Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/41247
Title: Delivery is key: lessons learnt from developing splice-switching antisense therapies.
Authors: 
Keywords: 
Mesh: 
Issue Date: 2017
Citation: EMBO Mol Med.2017 05;(9)5:545-557
Abstract: The use of splice-switching antisense therapy is highly promising, with a wealth of pre-clinical data and numerous clinical trials ongoing. Nevertheless, its potential to treat a variety of disorders has yet to be realized. The main obstacle impeding the clinical translation of this approach is the relatively poor delivery of antisense oligonucleotides to target tissues after systemic delivery. We are a group of researchers closely involved in the development of these therapies and would like to communicate our discussions concerning the validity of standard methodologies currently used in their pre-clinical development, the gaps in current knowledge and the pertinent challenges facing the field. We therefore make recommendations in order to focus future research efforts and facilitate a wider application of therapeutic antisense oligonucleotides.
PMID: 28289078
URI: https://hdl.handle.net/20.500.12530/41247
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos

Files in This Item:
File Description SizeFormat 
PMC5412803.pdf1.69 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.